Tarsus Pharmaceuticals (TARS) Accounts Payables (2023 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Accounts Payables of $24.1 million for Q1 2026, up 47.26% quarter-over-quarter from $16.4 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Accounts Payables (2023 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Accounts Payables history runs 4 years deep, the most recent figure standing at $24.1 million for Q1 2026.
- In Q1 2026, Accounts Payables changed N/A year-over-year to $24.1 million; the TTM figure through Mar 2026 stood at $24.1 million (changed N/A YoY), while the FY2025 annual figure was $16.4 million, up 73.98% from the prior year.
- Accounts Payables for Q1 2026 stood at $24.1 million, up from $16.4 million in the prior quarter.
- The five-year high for Accounts Payables was $24.1 million in Q1 2026, with the low at $400000.0 in Q1 2023.
- The 4-year median for Accounts Payables is $12.9 million (2024), against an average of $12.6 million.
- Peak annual rise in Accounts Payables reached 73.98% in 2025, while the deepest fall reached 73.98% in 2025.
- Tarsus Pharmaceuticals' Accounts Payables stood at $400000.0 in 2023, then jumped by 2254.75% to $9.4 million in 2024, then soared by 73.98% to $16.4 million in 2025, then surged by 47.26% to $24.1 million in 2026.
- Business Quant data shows TARS's Accounts Payables at $24.1 million in Q1 2026, $16.4 million in Q4 2025, and $9.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 40.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.14 Mn |
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | 16.39 Mn |
| Dec 31, 2024 | 9.42 Mn |
| Mar 31, 2023 | 400,000.00 |